生长抑素联合奥曲肽治疗肝硬化并发上消化道出血患者疗效及其对凝血功能指标的影响再观察

doi:10.3969/j.issn.1672-5069.2020.05.023

摘要/Abstract

摘要： 目的分析生长抑素联合奥曲肽治疗肝硬化并发上消化道出血患者疗效及其对凝血功能指标的影响。方法 2017年7月～2019年5月我院消化内科收治的肝硬化并发上消化道出血患者70例,采用随机数字表法将患者分为对照组35例和观察组35例。给予对照组静脉滴注奥曲肽,给予观察组奥曲肽联合生长抑素静脉滴注治疗3～7 d,随访1 w。使用CS-5100型全自动凝血分析仪检测血清凝血酶原时间(PT)、凝血酶时间(TT)、部分凝血酶活时间(APTT)和纤维蛋白原(FIB)水平。结果在治疗2 w末,观察组血清白蛋白水平为(33.5±3.1)g/L,显著高于对照组【(31.8±2.3)g/L,P<0.05】,而血清总胆红素和血氨水平分别为(30.9±10.2)μmol/L和(32.5±11.8)μmol/L,显著低于对照组【(41.4±14.3)μmol/L和(45.2±14.6)μmol/L,P<0.05】;观察组PT水平为(12.4±1.9) s,显著短于对照组【(14.1±2.3) s,P＜0.05】, TT为(18.2±2.1) s,显著短于对照组【(20.4±2.5) s,P＜0.05】, APTT为(34.5±4.8) s,显著短于对照组【(37.3±5.2) s,P＜0.05】, FIB水平为(2.4±0.6) g/L,显著高于对照组【(2.1±0.5) g/L,P＜0.05】;观察组止血时间和住院日为(20.7±3.1)h和(8.5±2.3)d,显著短于对照组【(24.6±3.9)h和(10.3±2.5)d,P＜0.05】,72 h再出血发生率为5.7%,显著低于对照组的20.0%(P＜0.05)。结论应用生长抑素联合奥曲肽治疗肝硬化并发上消化道出血患者能显著减少输血量,缩短止血时间和住院日,可能与改善了凝血功能异常有关。

关键词: 肝硬化, 上消化道出血, 生长抑素, 奥曲肽, 凝血功能, 治疗 , ,

Abstract: Objective The aim of this study was to analyze the efficacy and impact on blood coagulation functions of somatostatin and octreotide combination in the treatment of cirrhotic patients with upper gastrointestinal hemorrhage. Methods 70 cirrhotic patients with upper gastrointestinal hemorrhage were admitted to our hospital between July 2017 and May 2019, and they were randomly divided into control and observation group, with 35 cases in each. The patients in the control group were treated by intravenous infusion of octreotide and those in the observation group were treated by intravenous infusion of somatostatin and octreotide combination for 3 to 7 days. All patients were followed-up for two weeks. Blood prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT) and fibrinogen (FIB) were monitored. Results At the end of two week treatment, blood albumin level in the combination group was (33.5±3.1)g/L, significantly higher were than 【(31.8±2.3)g/L, P<0.05】, while serum bilirubin and blood ammonia levels (30.9±10.2)μmol/L and (32.5±11.8)μmol/L, much lower than 【(41.4±14.3)μmol/L and (45.2±14.6)μmol/L, respectively, P<0.05】 in the control; the PT was (12.4±1.9) s, significantly shorter than 【(14.1±2.3) s, P＜0.05】, the TT was (18.2±2.1) s, significantly shorter than 【(20.4±2.5) s, P＜0.05】, the APTT was (34.5±4.8) s, much shorter than 【(37.3±5.2) s, P＜0.05】, and the FIB level was (2.4±0.6) g/L, significantly higher than 【(2.1±0.5) g/L, P＜0.05】 in the control; the hemostasis time and hospital stay in the combination group were (20.7±3.1)h and (8.5±2.3)d, significantly shorter than 【(24.6±3.9)h and (10.3±2.5)d, P＜0.05】 in the control, and the incidence of 72 hour re-bleeding was 5.7%, significantly lower than 20.0%(P＜0.05) in the control. Conclusion The combination of somatostatin and octreotide in the treatment of cirrhotic patients with upper gastrointestinal hemorrhage greatly reduce the amount of blood transfusion, shorten the hemostasis time and hospital stay, which might be related to the correction of abnormal coagulation function.

Key words: Liver cirrhosis, Upper gastrointestinal hemorrhage, Somatostatin, Octreotide, Coagulation function, Therapy

杨熹, 宋冬梅, 华敏. 生长抑素联合奥曲肽治疗肝硬化并发上消化道出血患者疗效及其对凝血功能指标的影响再观察[J]. 实用肝脏病杂志, 2020, 23(5): 695-698.

Yang Xi, Song Dongmei, Hua Min.. Efficacy and impact on blood coagulation functions of somatostatin and octreotide combination in the treatment of cirrhotic patients with upper gastrointestinal hemorrhage[J]. Journal of Practical Hepatology, 2020, 23(5): 695-698.

参考文献

[1] Noveloso B, Bastiampillai B, Perni N, et al. Antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal bleeding. Am Fam Physician, 2017, 95(9): 582-582.
[2] Li Y, Han B, Li H, et al. Effect of admission time on the outcomes of liver cirrhosis with acute upper gastrointestinal bleeding: regular hours versus off-hours admission. Can J Gastroenterol Hepatol, 2018, 2018(1): 3541365.
[3] Poddar U. Diagnostic and therapeutic approach to upper gastrointestinal bleeding. Paediatr Int Child Health, 2019, 39(1): 18-22.
[4] Nardone G, Compare D, Martino A, et al. Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: a position paper of the italian society of gastroenterology (sige). Dig Liver Dis, 2018, 50(6): 542-548.
[5] 徐小元, 丁惠国, 贾继东, 等. 肝硬化门静脉高压食管胃静脉曲张出血防治指南(2015年). 中华胃肠内镜电子杂志, 2015, 2(4): 1-21.
[6] Purbey B K, Gurung R B, Panday R, et al. The etiology of upper gastrointestinal bleeding in patients with liver cirrhosis in dhulikhel hospital. KUMJ, 2017, 15(60): 292-295.
[7] Miyagi S, Fujio A, Tokodai K, et al. Successful case of somatostatin analog stopping gastrointestinal bleeding, one of the most frequent complications after simultaneous pancreas-kidney transplantation: a case report. Transplant Proc, 2016, 48(3): 985-987.
[8] Neophytou H, Mathieu A, Monseu M, et al. Upper gastrointestinal haemorrhage due to a small extra-papillary duodenal neuroendocrine tumour expressing somatostatin. Ann Endocrinol, 2015, 76(6): 697-701.
[9] Delaney M, Greene C J. Emergency department evaluation and management of patients with upper gastrointestinal bleeding. Emerg Med Pract, 2015, 17(4): 1-18, 19.
[10] 王军, 彭浩. 特利加压素联合生长抑素治疗肝硬化食管胃底静脉曲张破裂出血疗效观察. 实用肝脏病杂志, 2015, 18(4): 418-419.
[11] Robertson M, Ng J, Abu S W, et al. Risk stratification in acute variceal bleeding: comparison of the aims-65 score to established upper gastrointestinal bleeding and liver disease severity risk stratification scoring systems in predicting mortality and rebleeding. Dig Endosc, 2019, 6(13): 43-48.
[12] Xu B, Liu J, Liu S, et al. Clinical effect of single covered stent and double covered stent on TIPS in the treatment of hemorrhage due to rupture of esophageal and gastric varices in cirrhosis and its influence on immune function. Exp Ther Med, 2019,18(6):4259-4264.
[13] Machlab S, Garcia-Iglesias P, Martinez-bauer e, et al.Diagnostic utility of nasogastric tube aspiration and the ratio of blood urea nitrogen to creatinine for distinguishing upper and lower gastrointestinal tract bleeding. Emergencias, 2018, 30(6): 419-423.
[14] Czuczejko J, Mila-Kierzenkowska C, Szewczyk-Golec K. Plasma α-glutathione S-transferase evaluation in patients with acute and chronic liver injury.Can J Gastroenterol Hepatol, 2019, 2019:5850787.
[15] Wu C K, Yang S C, Liang C M, et al. The role of antibiotics in upper gastrointestinal bleeding among cirrhotic patients without major complications after endoscopic hemostasis. J Gastroenterol Hepatol, 2019, 3(8): 127-129.
[16] Iqbal S, Likhtshteyn M, O'Brien D, et al. Duodenal varix rupture - a rare cause of fatal gastrointestinal hemorrhage: a case report and review of literature. Am J Med Case Rep, 2019, 7(4): 62-66.
[17] Li Y, Li H, Zhu Q, et al. Effect of acute upper gastrointestinal bleeding manifestations at admission on the in-hospital outcomes of liver cirrhosis: hematemesis versus melena without hematemesis. Eur J Gastroenterol Hepatol, 2019, 31(11): 1334-1341.
[18] Nakajima-Doi S, Seguchi O, Shintani Y, et al. Experience of the use of octreotide for refractory gastrointestinal bleeding in a patient with jarvik2000((r)) left ventricular assist device. J Artif Organs, 2019, 22(4): 334-337.
[19] Sridharan K, Sivaramakrishnan G. Vasoactive agents for the management of variceal bleeding: a mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials. Drug Res (Stuttg), 2019, 69(9): 487-495.
[20] Frago S, Alcedo J, Martin PE, et al. Long-term results with lanreotide in patients with recurrent gastrointestinal angiodysplasias bleeding or obscure gastrointestinal bleeding. benefits in efficacy and procedures consumption. Scand J Gastroenterol, 2018, 53(12): 1496-1502.
[21] Yang T, Zheng TH, Zhao Q, et al. Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats. Pharm Biol, 2020,58(1):1-7.
[22] Li Z, Chen B, Dong W, et al. MKL1 promotes endothelial-to-mesenchymal transition and liver fibrosis by activating TWIST1 transcription. Cell Death Dis, 2019,10(12):899.
[23] Joo I, Kim SY, Park HS, et al. Validation of a new point shear-wave elastography method for noninvasive assessment of liver fibrosis: A prospective multicenter study. Korean J Radiol, 2019,20(11):1527-1535.